Home › Cancro ovarico › Minnesota › Rochester
Studi clinici su Cancro ovarico a Rochester, MN
29 studi su Cancro ovarico cercano partecipanti presso sedi a Rochester e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
In reclutamentoFase 2
- Mayo Clinic in Rochester, Rochester
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
In reclutamento
- Mayo Clinic, Rochester
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
In reclutamentoStudio osservazionale
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
In reclutamentoStudio osservazionale
- Mayo Clinic Rochester, Rochester
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
In reclutamentoFase 1/2
- Mayo Clinic - Rochester, Rochester
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
In reclutamentoFase 3
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
In reclutamentoFase 1
- Mayo Clinic - Rochester, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
In reclutamentoFase 1/2
- Mayo Rochester, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
In reclutamentoStudio osservazionale
- Mayo Clinic (Rochester), Rochester
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
In reclutamentoFase 2/3
- Mayo Clinic in Rochester, Rochester
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
In reclutamento
- Mayo Clinic in Rochester, Rochester
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
In reclutamentoFase 3
- Mayo Clinic in Rochester, Rochester
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Mayo Clinic (Minnesota), Rochester
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
In reclutamentoFase 2
- Mayo Clinic, Rochester
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
In reclutamentoFase 3
- Mayo Clinic Methodist Campus, Rochester
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
In reclutamentoFase 1/2
- The Mayo Clinic, Rochester
Lead-212 PSV359 Therapy for Patients With Solid Tumors
In reclutamentoFase 1/2
- Mayo Clinic in Rochester, Minnesota, Rochester
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
In reclutamentoFase 1
- Mayo Clinic, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
In reclutamentoFase 1/2
- Mayo Clinic - Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
In reclutamentoFase 1/2
- Mayo Clinic Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
In reclutamento
- Mayo Clinic, Rochester
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
In reclutamentoFase 3
- Mayo Clinic, Rochester
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
In reclutamento
- Mayo Clinic, Rochester
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
In reclutamentoFase 1/2
- Mayo Clinic, Rochester
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
In reclutamentoFase 1
- Mayo Clinic in Rochester, Rochester
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
In reclutamento
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Mayo Clinic, Rochester
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
In reclutamentoFase 2
- Mayo Clinic, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #14, Rochester
Studi su Cancro ovarico in altre città
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Altri studi a Rochester
- Cancro al seno42 studi
- Cancro del polmone non a piccole cellule37 studi
- Cancro metastatico31 studi
- Cancro (tutti i tipi)30 studi
- Cancro colorettale29 studi
- Mieloma multiplo24 studi
- Cancro alla prostata22 studi
- Insufficienza cardiaca22 studi
- Cancro pancreatico22 studi
- Cancro ai polmoni20 studi
- Cancro dell'endometrio20 studi
- Leucemia linfatica cronica19 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.